GlassScriptPhysician profile
Christopher Jon Schreier
NPI 1164406344
$7,406.91
in general payments reported to CMS, 2019-2025
48 companies · $1,518 in 2025
The $1,518 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $786 · 2020: $672 · 2021: $1,053 · 2022: $1,285 · 2023: $1,138 · 2024: $956 · 2025: $1,518.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,430 · Consulting Fee: $175 · Education: $6.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,429.68 |
| Consulting Fee | $175.00 |
| Education | $6.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $779.35 | 2019-2025 | Farxiga, Breztri, Lokelma |
| Abbvie INC. | $771.01 | 2021-2025 | Vraylar, Ubrelvy |
| Novo Nordisk INC | $726.79 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $514.69 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $464.78 | 2019-2025 | Prolia, Otezla, Repatha |
| Glaxosmithkline, LLC. | $438.86 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novartis Pharmaceuticals Corporation | $431.32 | 2019-2023 | |
| Pfizer INC. | $338.89 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $293.82 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $215.50 | 2019-2025 | Xifaxan |
| Exact Sciences Corporation | $213.66 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $203.92 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Abbott Laboratories | $152.51 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Merck Sharp & Dohme LLC | $148.76 | 2019-2025 | Gardasil 9, Capvaxive, Belsomra |
| Otsuka America Pharmaceutical, INC. | $141.51 | 2020-2025 | Rexulti, Abilify Maintena |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Schreier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.